KEAP1: Difference between revisions
CSV import |
CSV import |
||
| Line 35: | Line 35: | ||
[[Category:Histone demethylases]] | [[Category:Histone demethylases]] | ||
[[Category:Genes on human chromosome X]] | [[Category:Genes on human chromosome X]] | ||
<gallery> | |||
File:KEAP1_NRF2_modulating_antitumor_response.jpg|KEAP1 NRF2 modulating antitumor response | |||
File:KEAP1_NRF2_signaling_pathway.jpg|KEAP1 NRF2 signaling pathway | |||
File:KEAP1_and_NRF2_interacting_with_cellular_metabolism.jpg|KEAP1 and NRF2 interacting with cellular metabolism | |||
</gallery> | |||
Latest revision as of 04:09, 18 February 2025
KDM6A, also known as lysine-specific demethylase 6A, is a gene that encodes a protein involved in the regulation of gene expression through the demethylation of histone proteins. This protein is part of the Jumonji C (JmjC) domain-containing family of histone demethylases, which play a critical role in the epigenetic regulation of chromatin structure and function.
Function[edit]
KDM6A is responsible for the demethylation of tri-methylated lysine 27 on histone H3 (H3K27me3), a key epigenetic mark associated with transcriptional repression. By removing this methyl group, KDM6A activates gene expression by altering chromatin structure, making it more accessible to transcriptional machinery. This process is crucial for various cellular processes, including differentiation, development, and the maintenance of stem cell pluripotency.
Structure[edit]
The KDM6A protein contains several important domains, including the JmjC domain, which is essential for its demethylase activity. The protein also has tetratricopeptide repeat (TPR) domains that facilitate protein-protein interactions, allowing KDM6A to form complexes with other proteins involved in chromatin remodeling.
Clinical Significance[edit]
Mutations in the KDM6A gene have been implicated in several human diseases. Notably, KDM6A is associated with Kabuki syndrome, a rare genetic disorder characterized by distinctive facial features, growth delays, and intellectual disabilities. Additionally, KDM6A mutations have been identified in various cancers, including bladder cancer and multiple myeloma, where they may contribute to tumorigenesis by disrupting normal epigenetic regulation.
Research and Therapeutic Potential[edit]
Given its role in epigenetic regulation, KDM6A is a target of interest for therapeutic intervention. Inhibitors of KDM6A and related demethylases are being explored as potential treatments for cancers and other diseases where dysregulation of histone methylation is a factor. Understanding the precise mechanisms by which KDM6A influences gene expression and cellular function remains an active area of research.
Also see[edit]
-
KEAP1 NRF2 modulating antitumor response
-
KEAP1 NRF2 signaling pathway
-
KEAP1 and NRF2 interacting with cellular metabolism